Advertisement

Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives

  • Dursun Ceylan
  • Sevda ErerEmail author
  • Mehmet Zarifoğlu
  • Nevin Türkeş
  • Güven Özkaya
Original Article
  • 51 Downloads

Abstract

Objective

In this study, quality of life and psychiatric comorbid disorders were investigated in patients with cervical dystonia and their spouses and we also investigated the effect of botulinum toxin (BTX) treatment on these parameters.

Material and method

Thirty patients with cervical dystonia (CD) on BTX treatment and their spouses (n = 30) were included. Beck Depression Scale (BDS), State-Trait Anxiety Inventory I and II (STAI-I, STAI-II), Hospital Anxiety Scale (HAS), Hospital Depression Scale (HDS) for psychiatric comorbid disease assessment, Toronto Western Spasmodic Torticollis Scale (TWSTRS) for disease activity assessment, and Craniocervical Dystonia Questionnaire (CDQ-24), Cervical Dystonia Impact Profile (CDIP-58), and Short Form 36 (SF-36) questionnaires for quality of life assessment were used. BDS, STAI-I and STAI-II, HAS, HDS, and SF-36 scales were also obtained from the spouses. The same tests were applied both before and 8 weeks after the BTX treatment.

Conclusion

In our study, an increase in psychiatric comorbid disorders such as depression and anxiety was observed and the quality of life was adversely affected in all areas in patients. In the spouses of the patients, the rates of psychiatric comorbid disorders such as depression and anxiety were found to be increased when compared to healthy subjects while vitality, mental health, and general health perception were found to be negatively affected.

Patients showed improvements in anxiety level, disease activity, and overall quality of life scales after BTX treatment.

Keywords

Cervical dystonia Botulinum toxin therapy Quality of life Depression Anxiety 

Notes

Funding

This research did not receive any grants or funding from any funding agencies. The authors have no funding to report.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Zurowski M, McDonald WM, Fox S, Marsh L (2013) Psychiatric comorbidities in dystonia: emerging concepts. Mov Disord 28.  https://doi.org/10.1002/mds.25501
  2. 2.
    Fitzpatrick R (1992) “Quality of Life Measures in Health Care”, Applications and Issues in Assessement. BMJ 305:1074–1077CrossRefGoogle Scholar
  3. 3.
    Page D, Butler A, Jahanshahi M (2007) Quality of life in focal, segmental and generalized dystonia. Mov Disord 23(3):341–347CrossRefGoogle Scholar
  4. 4.
    Queiroz MR, Chien HF, Barbosa ER (2011) Quality of life in individuals with cervical dystonia before botulinum toxin injection in a Brazilian tertiary care hospital. Arq Neuropsiquiatr 69:900–904CrossRefGoogle Scholar
  5. 5.
    Ben-Shlomo Y, Camfield L, Warner T, on behalf of the ESDE collaborative group (2002) What are the determinants of quality of life in people with cervical dystonia. J Neurol Neurosurg Psychiatry 72:608–614CrossRefGoogle Scholar
  6. 6.
    Pekmezovic T, Svetel M, Ivanovic N, Dragasevic N, Petrovic I, Tepavcevic DK, Kostic VS (2009) Quality of life in patients with focal dystonia. Clin Neurol Neurosurg 111:161–164CrossRefGoogle Scholar
  7. 7.
    Stamelou M, Edwards MJ, Hallett M, Bathia KP (2012) The non -motor syndrome of primary dystonıyia: clinical and pathophysiological implications. Brain 135:1668–1681CrossRefGoogle Scholar
  8. 8.
    Akın YA, Akbostanci C, Mercan N, Aksun Z, Sorgun M (2012) Retrospective evaluation of 118 cervical dystonic cases treated with botulinum toxin Turk. J Neurol 18(3):104–107Google Scholar
  9. 9.
    Jog M, Chouinard S, Hobson D et al (2011) Causes for treatment delays in dystonia and Hemifacial spasm: a Canadian SurveyCan. J Neurol Sci 38:704–711CrossRefGoogle Scholar
  10. 10.
    Tomic S, Petkovic I, Pucic T, Resan B et al (2016) Cervical dystonia and quality of life. Acta Neurol Belg 116:589–592CrossRefGoogle Scholar
  11. 11.
    Slawek J, Friedman A, Potulska A et al (2007) Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type a injections. Functl Neurol 22:95–100Google Scholar
  12. 12.
    Moraru E, Schnider P, Wimmer A, Wenzel T, Birner P, Griengl H et al (2002) Relation between depression and anxiety in dystonic patients: implications for clinical management. Depress Anxiety 16:100–103CrossRefGoogle Scholar
  13. 13.
    Muller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W (2002) The Austrian botulinum toxin and dystonia study group. The impact of blepharospasm and cervical dystonia on health related quality of life and depression. J Neurol 249:842–846CrossRefGoogle Scholar
  14. 14.
    Fabbri M, Superbo M, Defazio G, Scaglione CLM, Antelmi E, Basini G, Nassetti S, Pizza F, Plasmati R, Liguori R (2014) Quality of life in patients with craniocervical dystonia: Italian validation of the “cervical dystonia impact profile(CDIP-58)” and the “Craniocervical dystonia questionnaire (CDQ-24) ”. Neurol Sci 35:1053–1058CrossRefGoogle Scholar
  15. 15.
    Lim VK (2007) Health related quality of life in patients with dystonia and tehir caregivers in new Zeland and Australia. Mov Disord 22(7):998–1003CrossRefGoogle Scholar
  16. 16.
    Wollmer MA, Boer C, Kalak N et al (2012) Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res 46:574–581CrossRefGoogle Scholar
  17. 17.
    Kocaman G, Baslo MH, Hanağası H, Parman Y. İdyopatik servikal distonili hastalarda botulinum toksini uygulanmasından önce ve sonra kas aktivasyon paterninde görülen değişimlerin incelenmesi Nöropsikiyatri Arflivi 2009; 46: 39–43Google Scholar
  18. 18.
    Fabbrini G, Berardelli I, Moretti G, Pasquini M, Bloise M, Colosimo C et al (2010) Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord 25:459–465CrossRefGoogle Scholar
  19. 19.
    Hefter H, Benecke R, Erbguth F, Jost W, Reichel G, Wissel J (2013) An open label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin a (Dysport). BMJ Open 3:e0011853.  https://doi.org/10.1136/bmjopen-2012-001853 CrossRefGoogle Scholar
  20. 20.
    Jen MH, Kurth H (2014) Assessing the burden of illness from cervical dystonia using the Toronto Western spasmodic torticollis rating scale scores and health utility: a meta- analysis of baseline patient-level clinical trial data. J Med Econ 17(11):803–809CrossRefGoogle Scholar

Copyright information

© Fondazione Società Italiana di Neurologia 2019

Authors and Affiliations

  1. 1.Medical Faculty, Department of Neurology, Department of NeurologyUludag UniversityBursaTurkey
  2. 2.Medical Faculty, Department of BiostatisticsUludag UniversityBursaTurkey

Personalised recommendations